We are live on ! Find out more
YMAB

Y-mAbs Therapeutics
YMAB

Delisted

YMAB was delisted on the 15th of September, 2025.

Back to rankings

98 hedge funds and large institutions have $107M invested in Y-mAbs Therapeutics in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 31 increasing their positions, 36 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

3% more funds holding

Funds holding: 95 → 98 (+3)

0.42% more ownership

Funds ownership: 44.65% → 45.07% (+0.42%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

14% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 36

19% less capital invested

Capital invested by funds: $132M → $107M (-$25.2M)

Holders
98
Holders Change
+3
Holders Change %
+3.16%
% of All Funds
1.56%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
9
Increased
31
Reduced
36
Closed
6
Calls
$16K
Puts
–
Net Calls
+$16K
Net Calls Change
-$9K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$2.23M
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$915K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$653K
4
GCP
GSA Capital Partners
United Kingdom
+$540K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$430K

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.77M
2
CSS
Cubist Systematic Strategies
Connecticut
-$594K
3
Two Sigma Investments
Two Sigma Investments
New York
-$534K
4
AllianceBernstein
AllianceBernstein
Tennessee
-$522K
5
N
Nuveen
North Carolina
-$387K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$13.5M -$340K -58,423 -2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$12.2M +$28.5K +4,899 +0.2%
SI
3
Sofinnova Investments
California
$12M – – –
PCH
4
Polar Capital Holdings
United Kingdom
$11.5M – – –
D.E. Shaw & Co
5
D.E. Shaw & Co
New York
$7.35M +$430K +73,813 +6%
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$4.42M +$915K +157,173 +24%
State Street
7
State Street
Massachusetts
$4.04M -$20.4K -3,509 -0.5%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$3.87M -$4.84K -831 -0.1%
Jacobs Levy Equity Management
9
Jacobs Levy Equity Management
New Jersey
$2.89M -$199K -34,092 -6%
Citadel Advisors
10
Citadel Advisors
Florida
$2.26M +$2.23M +382,794 +1,215%
Goldman Sachs
11
Goldman Sachs
New York
$2.12M -$77.5K -13,304 -3%
N
12
Nuveen
North Carolina
$1.95M -$387K -66,432 -16%
Millennium Management
13
Millennium Management
New York
$1.89M +$101K +17,347 +5%
Northern Trust
14
Northern Trust
Illinois
$1.76M -$31.1K -5,335 -2%
Los Angeles Capital Management
15
Los Angeles Capital Management
California
$1.66M +$192K +32,994 +12%
Prudential Financial
16
Prudential Financial
New Jersey
$1.56M +$209K +35,900 +14%
Charles Schwab
17
Charles Schwab
California
$1.36M -$44.6K -7,651 -3%
AQR Capital Management
18
AQR Capital Management
Connecticut
$1.34M +$268K +45,982 +23%
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$1.32M +$653K +112,091 +87%
Renaissance Technologies
20
Renaissance Technologies
New York
$1.29M +$122K +20,890 +10%
Two Sigma Advisers
21
Two Sigma Advisers
New York
$1.1M -$46.6K -8,000 -4%
MSKCC
22
Memorial Sloan Kettering Cancer Center
New York
$1.04M – – –
Connor, Clark & Lunn Investment Management (CC&L)
23
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1M -$11K -1,885 -1%
SCM
24
Soleus Capital Management
Connecticut
$857K – – –
GCP
25
GSA Capital Partners
United Kingdom
$748K +$540K +92,765 +208%
1
2 3 4 5

YMAB Hedge Fund Activity: Q3 2023 in Review

98 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q3 2023, worth a combined $107M — down 19% from $132M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new YMAB positions and 6 closed out — a net gain of 3 holders — while 31 added to existing stakes and 36 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $2.23M. The largest seller was Point72 Asset Management, cutting an estimated $1.77M.

  • 98 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q3 2023, up from 95 in Q2 2023.
  • Funds reported $107M of Y-mAbs Therapeutics stock for Q3 2023, down 19% quarter-over-quarter.
  • 9 funds opened new Y-mAbs Therapeutics positions in Q3 2023 and 6 closed out, a net change of +3 holders.
  • The largest Y-mAbs Therapeutics buyer in Q3 2023 was Citadel Advisors, an estimated $2.23M added.
  • The largest Y-mAbs Therapeutics seller in Q3 2023 was Point72 Asset Management, an estimated $1.77M sold.

Based on aggregated 13F filings for Q3 2023.